Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q− syndrome patients

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2007-07-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.0610477104PMID 17576924PMCID PMC1892786
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells.

  2007cited by this paper
• Chemical genomic screening for methylation‐silenced genes in gastric cancer cell lines using 5‐aza‐2′‐deoxycytidine treatment and oligonucleotide microarray

  2006cited by this paper
• Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

  2006cited by this paper
• Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly.

  2006cited by this paper
• Biological and Prognostic Significance of Chromosome 5q Deletions in Myeloid Malignancies

  2006cited by this paper
• SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix

  2006cited by this paper
• A pharmacodynamic study of 5-azacytidine in the P39 cell line.

  2006cited by this paper
• Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein

  2006cited by this paper
• p27KIP1 and GATA-1 are potential downstream molecules in activin A-induced differentiation and apoptosis pathways in CML cells.

  2006cited by this paper
• Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes.

  2005cited by this paper
• Immunomodulatory Drugs

  2005cited by this paper
• Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis.

  2005cited by this paper
• Efficacy of lenalidomide in myelodysplastic syndromes.

  2005cited by this paper
• SPARC Regulates Extracellular Matrix Organization through Its Modulation of Integrin-linked Kinase Activity*

  2005cited by this paper
• Antiapoptotic Role of Growth Factors in the Myelodysplastic Syndromes: Concordance Between In vitro and In vivo Observations

  2005cited by this paper
• Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy

  2005cited by this paper
• SPARC and tumor growth: Where the seed meets the soil?

  2004cited by this paper
• Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments

  2004cited by this paper
• SPARC regulates TGF‐beta1‐dependent signaling in primary glomerular mesangial cells

  2004cited by this paper
• The evolution of thalidomide and its IMiD derivatives as anticancer agents

  2004cited by this paper
• In patients with myelodysplastic syndromes response to rHuEPO and G‐CSF treatment is related to an increase of cytogenetically normal CD34+ cells

  2004cited by this paper
• Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.

  2004cited by this paper
• Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors.

  2003cited by this paper
• A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

  2003cited by this paper
• Exploration, normalization, and summaries of high density oligonucleotide array probe level data.

  2003cited by this paper
• Cleavage of the Matricellular Protein SPARC by Matrix Metalloproteinase 3 Produces Polypeptides That Influence Angiogenesis*

  2003cited by this paper
• Identification of the genes differentially expressed in human dendritic cell subsets by cDNA subtraction and microarray analysis.

  2002cited by this paper
• CANCER BIOLOGY: Enhanced: A Matter of Dosage

  2002cited by this paper
• Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.

  2002cited by this paper
• Thalidomide and its analogues have distinct and opposing effects on TNF‐α and TNFR2 during co‐stimulation of both CD4+ and CD8+ T cells

  2002cited by this paper
• Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

  2002cited by this paper
• Cancer biology. A matter of dosage.

  2002cited by this paper
• Z39Ig is co-expressed with activated macrophage genes.

  2002cited by this paper
• Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome.

  2002cited by this paper
• Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001

  2002cited by this paper
• Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide.

  2001cited by this paper
• Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

  2001cited by this paper
• Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications

  2001cited by this paper
• SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury.

  2001cited by this paper
• SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells.

  2001cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor β1, and activin a: Comparison of a cholangiocarcinoma cell line with primary cultures of non‐neoplastic biliary epithelial cells

  2000cited by this paper
• Activin A-induced HepG2 liver cell apoptosis: involvement of activin receptors and smad proteins.

  2000cited by this paper
• Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level.

  2000cited by this paper
• Combined immunophenotyping and FISH identifies the involvement of B‐cells in 5q‐ syndrome

  2000cited by this paper
• Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes

  2000cited by this paper
• Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

  2000cited by this paper
• Expression of activin A and follistatin core proteins by human prostate tumor cell lines.

  1999cited by this paper
• Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production.

  1999cited by this paper
• Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.

  1999cited by this paper
• Myelodysplasia.

  1999cited by this paper
• Chromosomal basis of adenocarcinoma of the prostate.

  1999cited by this paper
• Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production

  1999cited by this paper
• 5T4 oncofetal antigen in gastric carcinoma and its clinical significance

  1998cited by this paper
• Molecular cytogenetic delineation of the critical deleted region in the 5q− syndrome

  1998cited by this paper
• Low intercellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients.

  1997cited by this paper
• Native Recombinant Cyclophilins A, B, and C Degrade DNA Independently of Peptidylprolyl cis-trans-Isomerase Activity

  1997cited by this paper
• Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade.

  1996cited by this paper
• Allelotype of pancreatic adenocarcinoma using xenograft enrichment.

  1995cited by this paper
• Genes, chromosomes & cancer

  1995cited by this paper
• The 5q-syndrome.

  1994cited by this paper
• Human cyclophilin C: primary structure, tissue distribution, and determination of binding specificity for cyclosporins.

  1994cited by this paper
• Chromosome alterations in human small cell lung cancer: frequent involvement of 5q.

  1992cited by this paper
• Two cytoplasmic candidates for immunophilin action are revealed by affinity for a new cyclophilin: one in the presence and one in the absence of CsA.

  1991cited by this paper
• Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes.

  1991cited by this paper
• Molecular analysis of the cDNA for human SPARC/osteonectin/BM-40: sequence, expression, and localization of the gene to chromosome 5q31-q33.

  1988cited by this paper
• Distinct haematological disorder with deletion of long arm of No. 5 chromosome

  1974cited by this paper

• Evaluating the patterns of use and safety of lenalidomide treatment in myelodysplastic syndromes: a European, observational multi-registry study

  2026cites this paper
• Observational and Genetic Association of Myelodysplastic Syndromes (MDS) and Autoimmune Diseases in Adults.

  2026cites this paper
• Lenalidomide Efficacy in Patients with MDS and Del-5q: Real-World Data from the Hellenic (Greek) National Myelodysplastic & Hypoplastic Syndromes Registry (EAKMYS)

  2025cites this paper
• Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications

  2024cites this paper
• Improved Side Effect Profile of Alternate-Day Dosing of Lenalidomide

  2024cites this paper
• A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms

  2024cites this paper
• Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide

  2024cites this paper
• SPARC in hematologic malignancies and novel technique for hematological disease with its abnormal expression.

  2022cites this paper
• The role of lymphoid tissue SPARC in the pathogenesis and response to treatment of multiple myeloma

  2022cites this paper
• Dynamic changes in the levels of sCD62L and SPARC in chronic myeloid leukaemia patients during imatinib treatment

  2022cites this paper
• Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas

  2021cites this paper
• Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q

  2021influential citation
• High‐throughput, in‐depth and estimated absolute quantification of plasma proteome using data‐independent acquisition/mass spectrometry (“HIAP‐DIA”)

  2021cites this paper
• Genomic trajectory in leukemogenesis of myeloproliferative neoplasms: a case report

  2021cites this paper
• Targeting Casein Kinase 1 (CK1) in Hematological Cancers

  2020cites this paper
• Biology and Pathophysiology of MDS with del(5q)

  2020cites this paper
• L-leucin és lenalidomid együttes adásának kedvező hatása 5q- myelodysplasiás szindrómában

  2020cites this paper
• Cyclosporine Broadens the Therapeutic Potential of Lenalidomide in Myeloid Malignancies

  2020cites this paper
• Transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. Report of one case.

  2020cites this paper
• Repurposing of thalidomide and its derivatives for the treatment of SARS‐coV‐2 infections: Hints on molecular action

  2020cites this paper
• Myelodysplastic Syndromes

  2020cites this paper
• Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide

  2019cites this paper
• Molecular pathogenesis of myelodysplastic syndromes with deletion 5q

  2019cites this paper
• Association of eIF4E and SPARC Expression with Lymphangiogenesis and Lymph Node Metastasis in Hypopharyngeal Cancer.

  2018cites this paper
• SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q

  2018cites this paper
• Lenalidomide for the Treatment of MDS

  2018cites this paper
• Application of Lenalidomide on Diffused Large B-cell Lymphoma: Salvage, Maintenance, and Induction Treatment

  2018cites this paper
• THERAPEUTIC POTENTIAL OF TARGETING REACTIVE OXYGEN SPECIES (ROS) STRESS IN MYELODYSPLASTIC SYNDROME (MDS)

  2017cites this paper
• Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.

  2017cites this paper
• Concomitant Occurrence of Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukaemia after Lenalidomide Treatment for.

  2017cites this paper
• Etude moléculaire de l'évolution clonalede TP53 des Syndromes Myélodysplasiques avec del(5q) : conséquences sur la résistance au traitement et la progression du cancer

  2017cites this paper
• Role of Genetic Haploinsufficiency in the Biology and Targeted Therapy of Del(5q) Myelodysplastic Syndrome

  2017cites this paper
• Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway

  2017cites this paper
• Concomitant MDS with isolated 5q deletion and MGUS: case report and review of molecular aspects

  2017cites this paper
• Recurrent genetic defects on chromosome 5q in myeloid neoplasms

  2016cites this paper
• Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.

  2016cites this paper
• Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes.

  2016cites this paper
• A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes

  2016cites this paper
• The myelodysplastic syndromes

  2016cites this paper
• Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis

  2016cites this paper
• Cytogenetic place in managing myelodysplastic syndromes: an update by the Groupe francophone de cytogénétique hématologique (GFCH).

  2016cites this paper
• Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes

  2016cites this paper
• 8-year-sustained response in a patient with isolated del(5q) myelodysplastic syndrome undergoing continuous treatment with lenalidomide: a case report

  2016cites this paper
• Myelodysplastic Disorders, 5q-Syndrome

  2016influential citation
• The role of Toll/interleukin-1 receptor adaptor protein in the pathogenesis of myelodysplastic syndromes

  2015influential citation
• Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities.

  2015cites this paper
• Gene expression profiling in myelodysplastic syndrome after SPARC overexpression associated with Ara-C.

  2015cites this paper
• Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts

  2015cites this paper
• High level of full‐length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide

  2015cites this paper
• SPARC ectopic overexpression inhibits growth and promotes programmed cell death in acute myeloid leukemia transformed from myelodysplastic syndrome cells, alone and in combination with Ara-C treatment.

  2015cites this paper
• Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy

  2015cites this paper
• Genome‐wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide

  2015cites this paper
• Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)

  2015cites this paper
• New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.

  2015cites this paper
• Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS

  2015cites this paper
• SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.

  2014cites this paper
• Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells

  2014cites this paper
• Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis

  2014cites this paper
• The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.

  2014cites this paper
• Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide

  2014cites this paper
• Clinical Medicine Insights: Blood Disorders

  2014cites this paper
• Loss of SPARC protects hematopoietic stem cells from chemotherapy toxicity by accelerating their return to quiescence.

  2014cites this paper
• Molecular Diagnostics of Myeloid Neoplasms

  2014cites this paper
• Ribosomopathies: Mechanisms of Disease

  2014cites this paper
• Hematopoietic Cell Transplantation for Older Patients with MDS

  2014cites this paper
• A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia.

  2014cites this paper
• Beyond TGFβ: roles of other TGFβ superfamily members in cancer

  2013cites this paper
• Therapeutics , Targets , and Chemical Biology Lenalidomide Inhibits Lymphangiogenesis in Preclinical Models of Mantle Cell Lymphoma

  2013influential citation
• Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi

  2013cites this paper
• TP53 mutations in myelodysplastic syndromes with deletion of 5q

  2013cites this paper
• Lenalidomide as a novel treatment of acute myeloid leukemia

  2013cites this paper
• A Personalized Molecular Pathogenesis of MDS

  2013cites this paper
• Chromosome 5q deletion is extremely rare in patients with myelofibrosis.

  2013cites this paper
• Loss of sparc protects hematopoietic stem cells from the toxic effects of repeated cycles of chemotherapy by accelerating their return to quiescence

  2013cites this paper
• Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes

  2013influential citation
• The Biology of Myelodysplastic Syndrome Associated with Isolated del(5q)

  2013cites this paper
• Lenalidomide: A Review of its Use in Patients with Transfusion-Dependent Anaemia due to Low- or Intermediate-1-Risk Myelodysplastic Syndrome Associated with 5q Chromosome Deletion

  2013influential citation
• Interrogation of EpoR Fidelity in Myelodysplastic Syndrome Hematopoiesis and Stabilization by the Immunomodulatory Agent, Lenalidomide

  2013influential citation
• Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma.

  2013cites this paper
• Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program

  2013cites this paper
• Downregulation but lack of promoter hypermethylation or somatic mutations of the potential tumor suppressor CXXC5 in MDS and AML with deletion 5q

  2013cites this paper
• SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation

  2013cites this paper
• Myelodysplastic syndromes: toward a risk-adapted treatment approach

  2013cites this paper
• Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34+ cells from patients with del(5q) myelodysplastic syndrome

  2013cites this paper
• Lenalidomide Alone and in Combination for Chronic Lymphocytic Leukemia

  2013cites this paper
• Combination of Azacitidine and Lenalidomide in Myelodysplastic Syndromes or acute Myeloid Leukemia—a wise Liaison?

  2013cites this paper
• MYELODYSPLASTIC SYNDROME WITH DEL(5Q) AND LENALIDOMIDE

  2013cites this paper
• Management of Low-Risk MDS

  2013cites this paper
• Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial.

  2013cites this paper
• The myelodysplastic syndromes: diagnosis, prognosis and therapy

  2013cites this paper
• Lenalidomide, p53 and del(5q) Myelodysplastic Syndrome: Ribosome Stress Relief

  2013cites this paper
• Lenalidomide Therapy of Myelodysplastic Syndromes

  2013cites this paper
• Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy

  2013cites this paper
• Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.

  2013cites this paper
• Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.

  2012cites this paper
• Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study

  2012cites this paper
• Novel Biological Insights and Therapeutic Approaches in High-Risk Acute Myeloid Leukemia

  2012cites this paper
• Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice

  2012cites this paper
• Retinoid Differentiation Therapy for Common Types of Acute Myeloid Leukemia

  2012cites this paper
• SPOTLIGHT REVIEW Deregulation of microRNAs in myelodysplastic syndrome

  2012cites this paper